article thumbnail

Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma

PharmaShots

Shots: The companies collaborated to evaluate the safety, tolerability, PK, PD & preliminary antitumor activity of OTX-2002 as monotx. The preliminary results from the monotx.

article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

During the American Society of Clinical Oncology (ASCO) 2023 annual meeting, BioNTech revealed promising Phase I results for the pancreatic cancer drug BNT122 combined with the immune checkpoint inhibitor (ICI) atezolizumab. percent of the total mRNA therapy market by 2029. percent of the total mRNA therapy market by 2029.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lupin acquires nine brands of Medical Nutritional Institute in South Africa

Express Pharma

These products cater to a range of health issues such as metabolic syndrome, insulin resistance, cognitive function, skin health, inflammation, joint care, sleep quality, immune support, and women’s hormonal well-being. Mariaan du Plessis, CEO of MNI , shared her excitement about joining Pharma Dynamics. “We

article thumbnail

BioNTech to lead $2 bn mRNA-based oncology therapy market despite challenges: GlobalData

Express Pharma

The trial, conducted in collaboration with Memorial Sloan Kettering Cancer Center and in partnership with Genentech, combines BNT122 with the immune checkpoint inhibitor (ICI) atezolizumab. OTX-2002 from Omega Therapeutics is an mRNA therapy anticipated to generate $658 million in global sales, representing 33.2

article thumbnail

mRNA non-vaccine therapeutics to generate $2 billion by 2028

European Pharmaceutical Review

GlobalData stated that if development is successful for Ultragenyx’s OTX-2002 , which has potential to be the first programmable epigenetic medicine, it could generate $1.6 billion during 2028. The post mRNA non-vaccine therapeutics to generate $2 billion by 2028 appeared first on European Pharmaceutical Review.

article thumbnail

Key developments: mRNA vaccines and therapeutics

European Pharmaceutical Review

Initially developed to treat viral infections, mRNA vaccines deliver a piece of genetic material that instructs the body to make a protein fragment of a target pathogen (such as a virus), which the immune system recognises and remembers 1 to respond to when exposed to the pathogen in the future.

Vaccines 105
article thumbnail

Sore Throat

RX Note

Indications for Referral Sore throat duration >2 weeks or hoarseness of longer than 3 weeks' duration Suggests nonacute cause and require further investigation Difficulty in swallowing ( dysphagia ) Suggests sinister pathology Patents taking medications that can interfere with the immune response (e.g.